Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Tumor necrosis factor receptor-associated periodic syndrome managed with the couple canakinumab-alendronate.

Clinical rheumatology - 1 Apr 2015

Lopalco Giuseppe, Rigante Donato, Vitale Antonio, Frediani Bruno, Iannone Florenzo, Cantarini Luca

Abstract excerpt

Management of tumor necrosis factor receptor-associated periodic syndrome (TRAPS) is puzzling, and therapeutic choices can be complicated, due to both wide genetic heterogeneity and protean clinical phenotype. We report on a 35-year-old female who was diagnosed with TRAPS, after finding the V95M mutation on the TNFRSF1A gene; who was treated in order with etanercept, anakinra, and canakinumab (150 mg/every 8...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal, Humanized
Share to Etanercept

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hereditary Autoinflammatory Diseases

Share to Immunoglobulin G

Share to Interleukin 1 Receptor Antagonist Protein

Share to Osteoporosis

Share to Receptors, Tumor Necrosis Factor, Type I

Source

Identifiers

PMID: 24609716
DOI: 10.1007/s10067-014-2556-8

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Tumor necrosis factor receptor-associated periodic syndrome managed with the couple canakinumab-alendronate.PMID 24609716Read ↗

Canakinumab for the treatment of TNF-receptor associated periodic syndrome.Semantic proximity Read ↗

The most recent advances in pathophysiology and management of tumour necrosis factor receptor-associated periodic syndrome (TRAPS): personal experience and literature review.Semantic proximity Read ↗

[Tumor necrosis receptor associated periodic syndrome (TRAPS): State of the art].Semantic proximity Read ↗

Delights and let-downs in the management of tumor necrosis factor receptor-associated periodic syndrome: the canakinumab experience in a patient with a high-penetrance T50M TNFRSF1A variant.Semantic proximity Read ↗

Key facts and hot spots on tumor necrosis factor receptor-associated periodic syndrome.Semantic proximity Read ↗

TNF receptor-associated periodic syndrome (TRAPS): Description of a novel TNFRSF1A mutation and response to etanerceptSemantic proximity Read ↗

Tumour necrosis factor receptor-associated periodic syndrome caused by a rare mutation in the TNFRSF1A gene, and with excellent response to etanercept treatment.Semantic proximity Read ↗

Atypical clinical presentation of a severe Tumor Necrosis Factor Receptor-associated Periodic Syndrome (TRAPS) without mutation in the TNFRSF1A gene and good response to anakinra. Case report of a ten year old girl with fever, skin edema and abdominal pain (AID-registry)Semantic proximity Read ↗

TNF receptor-associated periodic syndrome (TRAPS): a new cause of joint destruction?Semantic proximity Read ↗

TNF-receptor-associated periodic syndrome (TRAPS): an autosomal dominant multisystem disorder.Semantic proximity Read ↗

Canakinumab efficacy and long-term tocilizumab administration in tumor necrosis factor receptor-associated periodic syndrome (TRAPS).Semantic proximity Read ↗

[TNF receptor-associated periodic syndrome (TRAPS) in Japan: clinical characterization, pathogenesis, diagnostic criteria, and treatment].Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.